Interpace Biosciences, Inc. (IDXG) proposes a firm-commitment underwritten offering of 3,100,000 shares of common stock. The estimated price range is $6.00 to $7.00 per share, with final pricing to be set with the underwriter. A 30-day option permits the underwriter to buy up to 465,000 additional shares to cover over-allotments.
At an assumed $6.50 per share, Interpace estimates net proceeds of approximately $17.9 million, or $20.8 million if the option is fully exercised. It plans to use proceeds for working capital, capital expenditures and general corporate purposes; some may support development of pancreatic cyst and Barrett’s Esophagus tests or investments in complementary businesses, technologies, products or assets. Closing is contingent on conditional Nasdaq listing approval; if the application is not approved, Interpace will not complete the offering.
Interpace focuses on its ThyGeNEXT and ThyraMIRv2 thyroid tests after discontinuing PancraGEN following loss of Medicare reimbursement. Its thyroid-only pro forma results report 2025 revenue of $34.8 million and adjusted EBITDA of $4.4 million, excluding PancraGEN revenue and related costs. At the assumed price, the company estimates immediate net tangible book value dilution of $2.03 per share for purchasers.